Edition:
United States

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

46.05USD
4:00pm EDT
Change (% chg)

$1.98 (+4.49%)
Prev Close
$44.07
Open
$46.91
Day's High
$47.61
Day's Low
$44.38
Volume
495,679
Avg. Vol
401,005
52-wk High
$71.22
52-wk Low
$41.16

Chart for

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 1.83
Market Cap(Mil.): $6,928.12
Shares Outstanding(Mil.): 156.14
Dividend: --
Yield (%): --

Financials

  ALKS.OQ Industry Sector
P/E (TTM): -- 173.69 32.21
EPS (TTM): -0.94 -- --
ROI: -9.58 -0.70 13.05
ROE: -11.99 -2.69 14.90

BRIEF-Alkermes Q1 GAAP Loss Per Share $0.40

* Q1 REVENUE $225.2 MILLION VERSUS I/B/E/S VIEW $219.3 MILLION

7:07am EDT

BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461

* ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Apr 16 2018

BRIEF-Alkermes Says CEO's FY 2017 Total Compensation Was $9.4 Mln VS $9.6 Mln In FY 2016

* ALKERMES PLC SAYS CHAIRMAN AND CEO RICHARD POPS' FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $9.6 MLN IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GPYT4o) Further company coverage:

Apr 10 2018

BRIEF-Alkermes CEO Says Does Not Believe Additional Trials Of Depression Drug Necessary

* CEO SAYS "WE DON'T BELIEVE ANY ADDITIONAL CLINICAL TRIALS ARE NECESSARY" ON CONF CALL WHEN ASKED ABOUT FDA'S DECISION ON ITS DEPRESSION DRUG‍​ Further company coverage:

Apr 02 2018

FDA refuses to review Alkermes' depression treatment, seeks more trials

Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval, citing a lack of evidence of its effectiveness.

Apr 02 2018

UPDATE 3-FDA refuses to review Alkermes' depression treatment, seeks more trials

* Shares fall as much as 22 percent (Adds comments from conference call; updates shares)

Apr 02 2018

FDA rejects application to review Alkermes' depression treatment

April 2 Alkermes Plc said on Monday the U.S. Food and Drug Administration rejected the application seeking approval for its experimental depression drug, citing insufficient evidence of effectiveness.

Apr 02 2018

BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461

* ALKERMES RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR ALKS 5461

Apr 02 2018

BRIEF-Alkermes Says Co, Units Entered Amendment To Amended And Restated Credit Agreement

* ALKERMES PLC SAYS ON MARCH 26, CO ,UNITS ENTERED AMENDMENT TO AMENDED & RESTATED CREDIT AGREEMENT, DATED AS OF SEPTEMBER 16, 2011 - SEC FILING

Mar 29 2018

BRIEF-Alkermes Appoints James Robinson As President And Chief Operating Officer

* ALKERMES APPOINTS JAMES ROBINSON AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

Competitors

Earnings vs. Estimates